FDA removes semaglutide from drug shortage list
The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can meet present and future demand, Novo Nordisk announced.On Feb. 21, the FDA updated its drug shortage list and listed the shortage of all doses of injectable semaglutide (Ozempic/Wegovy) as being resolved.
28mon MSN
The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...
Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.
A breakthrough study reveals that semaglutide, found in Ozempic and Wegovy, could help reduce alcohol cravings and heavy ...
The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback